English 
MeDiCU Inc., which provides the world’s largest emergency and intensive care database “OneICU,” has entered into a business partnership with Chugai Pharmaceutical Co., Ltd. regarding data utilization.
新薬の開発から実用化までには膨大な時間とコストがかかり、その中でも最も時間とコストがかかる臨床試験の効率化は、創薬研究の大きな課題です。特に、症状が急変する救急疾患の治療薬開発では、適切な患者群を見つけることが難しく、臨床試験の進行が遅れて開発プロセス全体が遅れることも珍しくありません。
“OneICU,” which 中外製薬 will now introduce, is the world’s largest medical big data collection, with biometric measurements from approximately 87,000 cases collected from patients in the ICUs (intensive care units) of eight university hospitals and core municipal hospitals across Japan. In addition to vital sign information measured once per minute, the database integrates and structures information from multiple facilities, which was previously thought to be nearly impossible to gather, including time-series data on therapeutic interventions in the ICU, severity scores, and outcomes at the time of discharge.
こちらもお読みください： KMバイオロジクス株式会社がM2Xを発表
By utilizing “OneICU,” it will be possible to understand the characteristics of medical institutions to which many patients who are the subjects of clinical trials are transported and use this information for patient selection. It is also expected to contribute to the efficiency of clinical trials by making it possible to determine in advance the most effective timing for medication based on data organized chronologically on how a patient’s condition changes after admission to the ICU.
本提携により、急性疾患治療薬の開発を効率化することで、救急・集中治療領域においてこれまで治療が困難とされてきた疾患の治療法の確立に繋げ、より質の高い医療の実現を目指します。
ソース PRタイムズ
日本語